| Bifunctional degrader scaffold (E3 recruiter)Abstract pharmacophoreprotac-bifunctional-corePage | Scaffold | c1ccc2c(c1)C(=O)N(C2=O)CCCC(=O)N | — | — | PROTAC · E3 · core · Shared pharmacophore / core scaffold. Anchor for the PROTAC / bifunctional degrader series… |
| ARV-110 (bavdegalutamide)Known compoundarv-110Page | Drug | CC1=CC(=CC(=C1)C2=NC(=NC(=C2)N3CCN(CC3)CCC… | Bifunctional degrader scaffold (E3 recruiter) | 30%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | clinical · AR · PROTAC · Clinical-stage candidate. ARV-110 (bavdegalutamide) in this family map. |
| ARV-471 (vepdegestrant)Known compoundarv-471Page | Drug | CC1=CC(=CC(=C1)C2=NC(=NC(=C2)N3CCN(CC3)CCC… | Bifunctional degrader scaffold (E3 recruiter) | 29%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | clinical · ER · PROTAC · Clinical-stage candidate. ARV-471 (vepdegestrant) in this family map. |
| BRD4 PROTAC example (dBET-class)Exploratory analogbrd4-protac-examplePage | Derivative | CC1=C(C(=O)N(C1C)c2ccc(C)cc2)CCCCN3C(=O)c4… | Bifunctional degrader scaffold (E3 recruiter) | 39%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | BRD4 · PROTAC · SAR / analog node exploring potency, selectivity, or ADME. |
| BTK PROTAC exampleExploratory analogbtk-protac-examplePage | Derivative | C=CC(=O)N1CCC[C@H]1c2ncnc3c2ccc(c3)NC(=O)C… | Bifunctional degrader scaffold (E3 recruiter) | 31%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | BTK · PROTAC · SAR / analog node exploring potency, selectivity, or ADME. |
| KRAS PROTAC cross-ref nodeExploratory analogkras-protac-xrefPage | Derivative | C[C@H]1CN(C(=O)C2=C(NC3=CC=CC(F)=C3)N=C(N2… | Bifunctional degrader scaffold (E3 recruiter) | — | KRAS · PROTAC · cross-ref · SAR / analog node exploring potency, selectivity, or ADME. |
| PROTAC SAR linker-length analogExploratory analog (rule-generated)protac-sar-linker-lengthPage | Derivative | CC1=CC(=CC(=C1)C2=NC(=NC(=C2)N3CCN(CC3)CCC… | ARV-110 (bavdegalutamide) | 29%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | SAR · linker · SAR exploration node. Derived analog of parent node in PROTAC / bifunctional degrader seri… |